Unlock powerful insights into non-small cell lung cancer therapies and global market dynamics

What is Epidemiology Intelligence?

Epidemiology Intelligence is your single source of patient population intelligence, featuring a unique combination of incidence and prevalence literature review, in-depth disease-specific forecasts, and U.S. claims-based insightsꟷnow including ethnicity data.

Download case studydownload

Five intuitive use cases

Benchmark market forecasts

Validate NSCLC forecasts with global prevalence, patient flow, and treatment rate data.

Validate investments and identify growth opportunities

Assess NSCLC treatment market potential by analyzing population trends and disease severity segmentation.

Position your product for success

Align your NSCLC therapy launch strategies with real-world demographics, comorbidities, and treatment dynamics.

Inform your R&D strategy

Guide NSCLC treatment development with comorbidity insights and real-world patient data across key markets.

Assess clinical trial feasibility

Evaluate NSCLC patient availability and site location potential to support trial planning and completion success.

10 or 20-year forecasts across 171 countries

Access disease-specific epidemiology with detailed analysis and annualized forecasts to support strategic planning and market assessment.

U.S. claims-based RWD

Gain patient segmentation based on age, gender, ethnicity and location granularity at both the national and state levels with insights from Clarivate U.S. Real-World Data.

Expert-driven disease modeling

Epidemiology forecasts are built by disease specialists using validated methods for confident, data-backed planning.

In-depth epidemiology coverage

Leverage prevalence data to support NSCLC market assessment—developed by a team of 40+ expert epidemiologists.

Critical questions explored to inform your strategy

What is the size of the drug-treatable population and where are they located?
In developing countries what impact will economic growth have on the number of people each year?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology over the forecast period?
Of all people with a disease, how many have been formally diagnosed in each country?
What is the size of a comorbid or niche population?

Request more informationnorth_east

Did you know that you can optimize your long-term NSCLC strategy with our Disease Landscape & Forecast insights report?

Request more information north_east

What’s included in the reports?

Forecasts through 2033: Patient-based 10-year market outlooks by indication.
Indication-specific strategy insights: Explore treatment trends, access and reimbursement, unmet needs, and many more.
Late-phase pipeline intelligence: Track Phase IIb/III assets and timelines to stay ahead of competitors.
Expert commentary: Interpret data with clarity from our disease analysts, therapy area experts, and epidemiologists.

Spotlight on China In-Depth for NSCLC

What are China In-Depth reports?

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

Optimize your long-term disease and development strategy in China.
Quantify market potential for your pipeline assets and those of your competitors.
Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
Gauge the commercial outlook and impact of key market events.